Co-morbidity burden in Parkinson’s disease : Comparison with controls and its influence on prognosis

Financial support This study was funded by Parkinson’s UK, the Scottish Chief Scientist Office, NHS Grampian endowments, the BMA Doris Hillier award, RS Macdonald Trust, the BUPA Foundation, and SPRING. The funders had no involvement in the study. Acknowledgements We acknowledge funding for the PINE study from Parkinson’s UK (G-0502, G-0914, G-1302), the Scottish Chief Scientist Office(CAF/12/05), the BMA Doris Hillier award, RS Macdonald Trust, the BUPA Foundation, NHS Grampian endowments and SPRING. We thank the patients and controls for their participation and the research staff who collected data and supported the study database.Peer reviewedPostprintPostprintPublisher PD

Early weight loss in parkinsonism predicts poor outcomes : evidence from an incident cohort study

This study was funded by Parkinson’s UK, the Scottish Chief Scientist Office, NHS Grampian endowments, the BMA Doris Hillier award, RS Macdonald Trust, the BUPA Foundation, and the Special Parkinson’s Research Interest Group (SPRING). The Article Processing Charge was funded by Parkinson's UK.Peer reviewedPublisher PD

Incidence and risk factors of institutionalisation in Parkinson's disease and atypical parkinsonism

Open Access via the Elsevier Agreement We would like to thank the patients for their participation and the research staff who collected data and supported the study database. The PINE study was funded by Parkinson's UK (grant numbers G0502, G0914, and G1302), the Scottish Chief Scientist Office (CAF/12/05, PCL/17/10), NHS Grampian endowments, the BMA Doris Hillier award, RS Macdonald Trust, the BUPA Foundation and SPRING. Yan Li is funded by a studentship from the Meikle Foundation.Peer reviewedPublisher PD

Genome-wide homozygosity and multiple sclerosis in Orkney and Shetland Islanders

There is strong evidence for both genetic and environmental risk factors comprising the aetiology of multiple sclerosis (MS). While much progress has been made in recent years in identifying common genetic variants using genome-wide association studies, alternative approaches have remained relatively neglected. The prevalence of MS in Orkney and Shetland is among the highest in the world. Previous studies have suggested that a higher degree of parental relatedness in these isolated communities may contribute to the high rates of MS, indicating that recessive effects have an important role in MS aetiology. The Northern Isles Multiple Sclerosis (NIMS) study investigated the potential role of genome-wide homozygosity in MS risk by genotyping 88 MS patients, 89 controls matched by age, sex and ancestry, and a further 89 controls matched for sex and ancestry, but passed the majority of lifetime risk of developing MS (>70 years of age). Three participants were removed on the basis of pedigree-genomic anomalies (n=263). Three measures of genome-wide homozygosity were generated for each individual, and association with MS was assessed using logistic regression models. No effect of genome-wide homozygosity was detected, indicating that inbreeding and consanguinity are not risk factors for MS in this population

Pre-hospital notification is associated with improved stroke thrombolysis timing

Peer reviewedPublisher PD

A systematic review of biomarkers for disease progression in Parkinson's disease

This article presents independent research funded by the National Institute for Health Research (NIHR) under its Programme Grants for Applied Research Programme (Grant Reference Number RP-PG-0707-10124).BACKGROUND: Using surrogate biomarkers for disease progression as endpoints in neuroprotective clinical trials may help differentiate symptomatic effects of potential neuroprotective agents from true disease-modifying effects. A systematic review was undertaken to determine what biomarkers for disease progression in Parkinson's disease (PD) exist. METHODS: MEDLINE and EMBASE (1950-2010) were searched using five search strategies. Abstracts were assessed to identify papers meriting review in full. Studies of participants with idiopathic PD diagnosed by formal criteria or clearly described clinical means were included. We made no restriction on age, disease duration, drug treatment, or study design. We included studies which attempted to draw associations between any tests used to investigate disease progression and any clinical measures of disease progression. The electronic search was validated by hand-searching the two journals from which most included articles came. RESULTS: 183 studies were included: 163 (89%) cross-sectional, 20 (11%) longitudinal. The electronic search strategy had a sensitivity of 71.4% (95% CI 51.1-86.0) and a specificity of 97.1% (95% CI 96.5-97.7). In longitudinal studies median follow-up was 2.0 years (IQR 1.1-3.5). Included studies were generally poor quality--cross-sectional with small numbers of participants, applying excessive inclusion/exclusion criteria, with flawed methodologies and simplistic statistical analyses. CONCLUSION: We found insufficient evidence to recommend the use of any biomarker for disease progression in PD clinical trials, which may simply reflect the poor quality of research in this area. We therefore present a provisional 'roadmap' for conducting future disease progression biomarker studies, and recommend new quality criteria by which future studies may be judged.Publisher PDFPeer reviewe

Age-related selection bias in Parkinson's disease research : are we recruiting the right participants?

Acknowledgements We acknowledge the earlier work of Dr Kate Taylor and Dr Dominique Twelves on the previous systematic review of incidence studies in Parkinson’s disease. Funding This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Authors report the following funding received during the conduct of this study: Dr Macleod: fellowship funding from the Chief Scientist Office of the Scottish Government and NHS Education for Scotland; grant funding Parkinson’s UK, the Academy of Medical Sciences, NHS Grampian Endowments, the Wellcome Trust, the University of Aberdeen. Dr Henery: financial support from the University of Aberdeen Dr Nwajiugo: none Dr Scott: none Dr Caslake: grant funding from Parkinson’s UK Dr Counsell: grant funding from the Chief Scientist Office of the Scottish Government, the PSP Association, and NHS Grampian Endowments.Peer reviewedPostprin